<DOC>
	<DOCNO>NCT00541086</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block use estrogen tumor cell . Anastrozole , letrozole , exemestane may fight breast cancer lower amount estrogen body make . It yet know whether give tamoxifen follow anastrozole , letrozole , exemestane effective give anastrozole , letrozole , exemestane alone treat breast cancer . PURPOSE : This randomized phase III trial study give tamoxifen follow either anastrozole , letrozole , exemestane see well work compare anastrozole , letrozole , exemestane alone treat postmenopausal woman hormone-responsive invasive breast cancer completely remove surgery .</brief_summary>
	<brief_title>Study Anastrozole , Letrozole , Exemestane With Without Tamoxifen Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To compare sequential tamoxifen 2 year follow anastrozole , letrozole , exemestane 3 year vs anastrozole , letrozole , exemestane 5 year term disease-free survival postmenopausal woman nonrecurrent , nonmetastatic invasive endocrine-responsive breast cancer . - To compare disease-free survival patient treat anastrozole v letrozole v exemestane . OUTLINE : This multicenter study . Patients stratify accord hormone receptor status ( estrogen receptor [ ER ] -positive progesterone [ PgR ] receptor-positive disease vs ER-positive PgR-negative disease vs ER-negative PgR-positive disease vs ER- PgR-positive disease ER PgR status unknown ) , HER-2/neu status ( positive [ 3+ IHC positive fluorescence situ hybridization ( FISH ) ] vs negative v unknown ) , prior chemotherapy ( none v adjuvant v neoadjuvant v adjuvant neoadjuvant ) , nodal status ( pN0 v pN1 v pN2 v pN3 ) . Patients randomize 1 6 treatment arm . - Arm I : Patients receive oral anastrozole daily 5 year . - Arm II : Patients receive oral exemestane daily 5 year . - Arm III : Patients receive oral letrozole daily 5 year . - Arm IV : Patients receive oral tamoxifen citrate daily 2 year follow oral anastrazole daily 3 year . - Arm V : Patients receive oral tamoxifen citrate daily 2 year follow oral exemestane daily 3 year . - Arm VI : Patients receive oral tamoxifen citrate daily 2 year follow oral letrozole daily 3 year . Treatment arm continue absence disease recurrence unacceptable toxicity . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer completely remove surgery Any T , N No recurrent metastatic disease Estrogen progesterone receptorpositive disease primary tumor , define 1 following : At least 10 % tumor cell positive immunohistochemistry At least 10 fmol/mg cytosol protein ligand bind assay Patients HER2/neu positive tumor eligible provide receive trastuzumab ( Herceptin® ) accord registered schedule PATIENT CHARACTERISTICS : Female Postmenopausal , define ≥ 1 following : Age ≥ 60 year Age 4559 satisfy 1 follow criterion : Amenorrhea ≥ 12 month AND intact uterus Amenorrhea ( secondary hysterectomy , hormone replacement therapy ( HRT ) , chemotherapy ) &lt; 12 month AND folliclestimulating hormone within postmenopausal range Underwent prior bilateral oophorectomy age &gt; 18 year No concurrent illness contraindicate adjuvant endocrine treatment No invasive breast cancer invasive malignancy within past 10 year , except adequately conebiopsied squamous cell basal cell skin cancer carcinoma situ cervix No concurrent disease would place patient unusual risk PRIOR CONCURRENT THERAPY : See Disease Characteristics Adjuvant neoadjuvant chemotherapy must complete prior study entry At least 1 month since prior concurrent HRT More 30 day since prior systemic investigational drug No prior tamoxifen part breast cancer prevention study Prior concurrent locoregional radiotherapy allow No concurrent experimental drug No concurrent bisphosphonates , unless indicate treatment osteoporosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>